Beware the Risks

References 

1. Bastian PJ, Carter BH, Bjartell A, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol. 2009;55:1321
   • Abstract
   • Full Text
   • Full-Text PDF (192 KB)
   • CrossRef
2. Miyamoto RK, Thompson IM. The reliability of digital rectal exam, PSA, repeat prostate biopsy and endorectal MRI for following patients with clinically localized prostate cancer on active surveillance. J Urol. 2008;179(suppl.):154;The Journal of Urology, abstract 435
   • Full-Text PDF (123 KB)
   • CrossRef
3. van den Bergh RC, Roemeling S, Roobol MJ, et al. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer—a review. Eur Urol. 2008;54:505
   • Abstract
   • Full Text
   • Full-Text PDF (367 KB)
   • CrossRef
4. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007;99:526
   • CrossRef
5. Suardi N, Capitanio U, Chun FK, et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer. 2008;113:2068
   • CrossRef